Radiographic progression-free survival as a surrogate endpoint for overall survival in first-line ARPi naïve metastatic castration-resistant prostate cancer
Results suggest rPFS is a valid surrogate for OS in first-line ARPi naïve mCRPC per IQWiG criteria. A statistically significant OS effect can be inferred for a trial demonstrating an upper confidence limit of HR < 0.83 in rPFS.
Authors
- Anja Haltner (ORCID: https://orcid.org/0000-0002-9829-7791)
- Alexander Niyazov (ORCID: https://orcid.org/0000-0003-1292-9661)
- Imtiaz A. Samjoo (ORCID: https://orcid.org/0000-0003-1415-8055)
- Pedro Coelho Barata (ORCID: https://orcid.org/0000-0002-8890-2951)
- Elena Castro (ORCID: https://orcid.org/0000-0002-3691-6454)
- Jane Chang
- S. Paganelli
- Di Wang
Institutions
- Pfizer (United States) (US)
- Medgar Evers College (US)
- Hospital Universitario 12 De Octubre (ES)
- University Hospitals Seidman Cancer Center (US)
- EVERSANA (Canada) (CA)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1093/oncolo/oyaf425
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- Exelixis
- Eisai
- EMD Serono